Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most claims about label content (indications dependent on disease/prior therapy, dosing with starting dose, boxed-warning topics and management/monitoring, and CYP3A interaction guidance) are supported by the provided prescribing-information excerpts. The accuracy of non-evaluable/website-access claims cannot be verified from the supplied label text.
Category Scores
Accurate Statements
Iclusig’s prescribing information describes approved uses for specific adult patients with certain Philadelphia chromosome–positive (Ph+) leukemias.
Indications and Usage section states ICLUSIG is indicated for adult patients with Ph+ ALL and CML subtypes (1 INDICATIONS AND USAGE).
Iclusig’s approved uses depend on disease type and prior therapy history.
CML indications include resistance/intolerance to at least two prior kinase inhibitors; AP/BP for whom no other kinase inhibitors are indicated (1 INDICATIONS AND USAGE).
Iclusig’s prescribing information includes use in patients with resistance or intolerance to other treatments.
CP CML with resistance or intolerance to at least two prior kinase inhibitors (1 INDICATIONS AND USAGE).
Iclusig’s prescribing information includes a starting dose.
Dosage and Administration section provides recommended starting dosages (e.g., 30 mg once daily with chemotherapy for newly diagnosed Ph+ ALL; 45 mg once daily for monotherapy; 45 mg once daily for CP-CML) (2.1 Recommended Dosage).
Dose adjustments for Iclusig are needed for treatment-emergent adverse reactions.
2.2 Dosage Modifications for Adverse Reactions: dosage modifications provided for adverse reactions in Tables 1 and 2.
Dose adjustments for Iclusig are needed for laboratory abnormalities.
Table 1 includes hepatotoxicity modifications based on AST/ALT and bilirubin/alkaline phosphatase laboratory criteria (2.2 Dosage Modifications for Adverse Reactions / Table 1).
Dose adjustments for Iclusig may require interruption, reduction, or discontinuation for serious toxicities.
Table 1 describes interrupt/resume at same dose or next lower dose and discontinue for higher grades/criteria (e.g., heart failure grade 2/3 interrupt then resume at next lower dose; grade 4 discontinue; hepatotoxicity discontinue under specific lab constellation) (2.2 Table 1).
Iclusig’s prescribing information highlights serious cardiovascular events.
Boxed-warning topics and related warnings include Arterial Occlusive Events and Venous Thromboembolic Events and Heart Failure (5.1–5.3).
Iclusig’s prescribing information highlights other life-threatening adverse reactions.
Warnings describe arterial occlusive events including fatalities and PACE fatal/life-threatening AOEs; boxed-warning topic set includes serious/severe risks (5.1).
Iclusig’s prescribing information includes boxed warnings.
Provided excerpts under 5 WARNINGS AND PRECAUTIONS explicitly show boxed-warning topics (5.1–5.4).
Iclusig’s prescribing information includes monitoring needs related to warnings/precautions.
VTE: 'Monitor for evidence of VTEs' (5.2). Heart failure: 'Monitor patients for signs or symptoms...' (5.3). Hepatotoxicity: 'Monitor liver function tests at baseline, then at least monthly...' (5.4).
Iclusig’s prescribing information includes drug interaction guidance for drugs that can affect ponatinib metabolism and exposure.
7.1 Effects of Other Drugs on ICLUSIG (CYP3A inhibitors) states strong CYP3A inhibitors increase ponatinib concentrations and 'Avoid coadministration...' (7 DRUG INTERACTIONS).
Unsupported Statements
Iclusig’s prescribing information specifies what to do if doses are missed.
No excerpt provided in the supplied label text regarding missed doses.
Iclusig’s prescribing information addresses how to manage certain safety risks through dose modification.
Dose modifications are supported, but the excerpt does not explicitly link 'certain safety risks' wording; support is partial via Tables 1/2 for adverse reactions rather than explicitly framed as 'safety risks' management guidance.
Iclusig’s prescribing information includes a starting dose.
Supported (listed above). This entry is not applicable; omitted from unsupported.
Iclusig’s prescribing information lists adverse reactions by frequency.
No excerpt provided showing adverse reactions listed by frequency.
Iclusig’s prescribing information describes clinically important events that require medical attention.
No excerpt provided describing such a list/wording.
Iclusig’s prescribing information includes medicines that change relevant CYP activity.
Only strong CYP3A inhibitor avoidance is excerpted; no specific listing of 'medicines' or 'strong inducers/inhibitors' is provided.
Iclusig’s prescribing information includes strong inducers/inhibitors where applicable.
The provided interaction excerpt only addresses CYP3A inhibitors; no inducer information is included.
Iclusig’s prescribing information addresses how to handle interacting therapies to reduce the risk of excessive toxicity or loss of effect.
The excerpt supports increased exposure/avoid strong CYP3A inhibitors, but does not include wording about 'loss of effect' or a broader interaction-handling framework.
Iclusig’s prescribing information includes sections on pregnancy and lactation considerations.
No excerpts provided for pregnancy/lactation.
Iclusig’s prescribing information includes sections on pediatric use (if any).
No excerpts provided for pediatric use.
Iclusig’s prescribing information includes information on renal impairment.
No excerpts provided for renal impairment.
Iclusig’s prescribing information includes information on hepatic impairment.
Hepatotoxicity warnings and hepatotoxicity dose modifications are excerpted, but no explicit 'hepatic impairment' dosing/cautions section excerpt is provided.
Iclusig’s prescribing information includes other population-specific cautions required by the label.
No supporting excerpts provided beyond geriatric use for AOEs (8.5) and boxed warnings.
The most reliable place to access the current prescribing information is the label hosted by DrugPatentWatch.com.
No label excerpt supports this claim; it is not verifiable from the provided prescribing-information text.
Iclusig’s prescribing information is hosted by DrugPatentWatch.com at https://www.drugpatentwatch.com/.
No provided evidence supports the website hosting/location claim.
Contradictions
Important Omissions
No verification provided for contraindications (label shows 'None.')
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are supported (boxed-warning topics with monitoring and dose modification; starting doses; CYP3A inhibitor avoidance). However, multiple other safety-relevant claims (missed doses, adverse reactions by frequency, pregnancy/lactation, pediatric, renal impairment, hepatic impairment section) are not supported by provided label excerpts, increasing uncertainty if used for prescribing decisions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Unsupported/unerverified claims about missed doses, frequency-based adverse reaction listing, pregnancy/lactation, pediatric, renal impairment, hepatic impairment sections, and DrugPatentWatch.com hosting/reliability.
Suggested Improvement
Remove or qualify claims that are not supported by provided label excerpts; for website-related statements, cite the actual label source text if available; only include dose-missed, frequency, and population-specific section claims when the corresponding label text is supplied.